Close Button Icon
Doptelet (avatrombopag) Tablets Logo

You are about to leave DOPTELETHCP.com and go to an external page.

Please note that Sobi is not responsible for the content of the website you are about to visit.

CONTINUE

Go back

This information is intended for healthcare professionals in the United States.

Are you a healthcare professional?

Yes

No
Close Button Icon

Discover the Doptelet Copay Program

Eligible commercially insured patients may qualify for the Doptelet Connect program

What's the program?

  • Eligible patients may pay as little as $0 for each Doptelet prescription
  • Annual maximum benefit up to $15,000

Eligible patients must:

  • Have commercial insurance that covers Doptelet
  • Not be enrolled in any state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
  • Be 18 years of age or older
  • Be a resident in the United States or a US Territory

How to enroll:

  • Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
  • Patients can enroll themselves as well as their caregivers
  • Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

  • Patients pay as little as $0 per prescription. Copay Program has an annual calendar cap of $15,000
  • The Copay Saving Program is void where prohibited by law, taxes, or restricted
  • This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
  • The Patient Copay Program for Doptelet is not insurance and is not intended to substitute for insurance
  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Program
  • Certain information pertaining to your use of the Copay Program will be shared with Sobi, Inc., the sponsor of the Copay Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
  • Acceptance in this Program is not conditioned on any past, present, or future purchase, including additional doses
  • Enrollment for the Copay Program is valid through the calendar year
  • Sobi reserves the right to change program terms at any time
Close Button Icon
  • For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
    • ITP Resources
    • Video Library
  • Request a Rep
  • For US healthcare professionals only

  • Important Safety Information
  • Prescribing Information
  • Patient Information Leaflet
  • For Patients
Doptelet (avatrombopag) Tablets Logo

For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
    • ITP Resources
    • Video Library
  • Request a Rep

Doptelet is broadly available** and covered on United Healthcare, Express Scripts, CVS Caremark and Aetna.

Formulary status is subject to change and does not imply clinical efficacy or safety.††

Learn more about our
access services here

**

Broadly available: covered for over 50% of patients on plan.

††

For specific information, please contact the patient's insurer. Individual access may vary by geography and plan benefit design. Third-party payment for prescription
drugs is affected by numerous factors, and Sobi makes no representation or guarantee concerning reimbursement or coverage for Doptelet or any other service or item.

DOPTELET CONNECTTM

Doptelet Connect offers access and reimbursement support, including information on patient healthcare coverage options and financial assistance.

Doptelet Connect

Doptelet Connect offers access and reimbursement support to help patients access Doptelet. Doptelet Connect provides information regarding patient healthcare coverage options and financial assistance information that may be available to help patients with financial needs.

For more information, call Doptelet Connect at 1-833-368-2663 Monday-Friday 8AM-8PM ET

Any questions? We're here to help!

Doptelet Connect can:

Doptelet Connect Help Tools

Evaluate a patient’s prescription coverage, including benefits investigation, prior authorization, and appeal assistance support.

Doptelet Connect Help Question Bubbles

Provide field reimbursement support through a single point of contact.

Doptelet Connect Financial Assistance Hand and Money

Provide financial assistance information

Doptelet Connect Help Question Bubbles

Identify potential financial assistance options that may be available to help eligible patients with financial needs.

Doptelet Connect Help Question Bubbles

Answer logistical questions and provide information and coordination around the specialty pharmacy fulfillment process.

Patient Assistance

Doptelet Connect can provide options that may be available to your patients. Call Doptelet Connect to help determine which offerings your patient may be eligible for:

Doptelet Copay Assistance Program*

The Doptelet Copay Assistance Program* is for eligible patients who have commercial prescription insurance. Patients may pay as little as $0 per prescription, up to a maximum of $15,000 per calendar year.

ENROLL NOW

See terms and conditions.

Doptelet Download Icon

Doptelet Copay Program

Outlines how the Doptelet Copay Program can help lower out-of-pocket costs for eligible patients receiving Doptelet

Pay as Little as $0 Doptelet Copay Icon

Doptelet Patient Assistance Program†

The Patient Assistance Program† provides Doptelet at no cost to patients who meet the eligibility requirements.

DOWNLOAD APPLICATION

View form en español


Doptelet Free Trial Offer†

The Doptelet Free Trial Offer† provides a 15-day supply of Doptelet, at no cost, to patients who are new to Doptelet and have ITP. The Free Trial Offer allows physicians and patients to evaluate a patient’s clinical response to Doptelet to determine whether it is the appropriate treatment.

DOWNLOAD FORM


In order to participate in the Doptelet Copay Assistance Program (Program), a patient must be 18 year or older and have commercial prescription insurance for Doptelet. The Program is not valid for patients whose prescriptions claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to Medicaid, Medicare, Medigap Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. This offer is not valid for cash paying patients. The Program is void where prohibited by law. Certain rules and restrictions apply. Sobi reserves the right to revoke, rescind or amend this offer without notice. This Program is not insurance.

Program subject to eligibility requirement and program terms and conditions.

How Doptelet Connect Works

Doptelet Download Icon

Prescription and Enrollment Form

Prescribes Doptelet and enrolls a patient into Doptelet Connect

View form en español

Doptelet Download Icon

Doptelet Connect Overview

Describes the Doptelet Connect support offerings available to your patients and your office

Doptelet Download Icon

Doptelet Connect Process Flow for Healthcare Professional (HCP) Offices

Explains relationship between the HCP offices and Doptelet Connect and the steps each may take during the access process

Doptelet Download Icon

Patient Consent Form

Authorization provides patient/caregiver access to Doptelet Connect

View form en español

Doptelet Access and Support Resource Guide

Offers a collection of digital resources for HCP office staff to navigate Doptelet access and reimbursement process.

DOWNLOAD

Inside the guide you will find…

Enrollment Guide

Doptelet Download Icon

Information to Help Complete the Prescription and Enrollment Form

Provides information on how to complete the Prescription and Enrollment Form

Doptelet Download Icon

Getting Started With Doptelet

Gives an overview of the Doptelet access process and the pathway options from prescription through continuing care

Accessing Doptelet Documents

Doptelet Download Icon

Doptelet Prior Authorization Resource Guide

Explains general steps in the PA process to help HCP offices get patients started on Doptelet

Doptelet Download Icon

Accessing Doptelet: Specialty Pharmacies and Distributors

Lists the contact information for the specialty pharmacies and distributors that are authorized to dispense Doptelet

Doptelet Download Icon

Coding Resource

Provides useful codes to identify appropriate patients and assists with the billing and reimbursement of Doptelet

Doptelet Download Icon

You’ve Been Prescribed Doptelet: Now What?

Outlines the process for patients in obtaining a Doptelet prescription with a Specialty Pharmacy

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

Sobi Rare Strength Logo
Terms of Use
Privacy Policy
Contact Us
Unsubscribe
White YouTube Logo

Doptelet is a registered trademark of AkaRx, Inc.
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Doptelet Connect is a trademark of AkaRx, Inc.
© 2022 Sobi, Inc. – All rights reserved

PP-14799   04/22

INDICATION & IMPORTANT
SAFETY INFORMATION
Open ISI Button
Close ISI Button

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Scroll To Top Button

This website uses cookies. By continuing to use this website, you consent to our use of these cookies.

Read more about our use of cookies